Global Gamma Knife Market, by Indication (Brain Metastasis, Arteriovenous Malformation (AVM), Trigeminal Neuralgia, Movement Disorders, Cancer and Others), by Anatomy (Neck and Head), by End-user (Hospitals, Clinics and Ambulatory Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
was valued at US$ 173.55 million
in 2019 and is expected to exhibit a CAGR of 3.2%
over the forecast period (2019-2027), as highlighted in a new report published by .
The rising number of neurological surgeries is expected to drive growth of the global gamma knife market over the forecast period. For instance, according to the Healthcare Cost and Utilization Project (HCUP) report, in 2014, 17.2 million hospital visits (ambulatory or inpatient) included invasive and therapeutic surgeries. Over half of these visits (9.9 million visits) occurred in ambulatory surgery (AS) settings, and the remaining 7.2 million were inpatient surgeries.
Increasing prevalence of brain tumors is expected to boost global gamma knife market growth. For instance, according to the Central Brain Tumor Registry of the United States (CBTRUS) 2018, the incidence of all primary malignant and non-malignant brain tumors, and other CNS tumors was 23.03 cases per 100,000 for 392,982 tumors in 2018. According to the same source, an estimated 86,970 new cases of primary malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the U.S. in 2019.
The global gamma knife market size is expected to witness significant growth during the forecast period, owing to increase in regulatory approvals for gamma knife products. For instance, in June 2015, Elekta, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Marking for Leksell Gamma Knife Icon. Which is the world’s most precise and sophisticated system for radiosurgery treatment of certain brain tumors, vascular malformations and functional disorders.
Browse 35 Market Data Tables and 33 Figures spread through 185 Pages and in-depth TOC on "Global Gamma Knife Market, by Indication (Brain Metastasis, Arteriovenous Malformation (AVM), Trigeminal Neuralgia, Movement Disorders, Cancer and Others), by Anatomy (Neck and Head), by End-user (Hospitals, Clinics and Ambulatory Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"
To know the latest trends and insights related to global gamma knife market, click the link below:
In July 2019, University of Minnesota launches exclusive gamma knife technology for radiation therapy, is used to treat brain tumor patients with the latest generation advanced radiosurgery technology. The radiosurgery works by focusing radiation beams from different angles to a small target.
Key Takeaways of the Global Gamma Knife Market:
- The global gamma knife market is expected to exhibit a CAGR of 3.2% over the forecast period (2019–2027) owing to increasing prevalence of brain tumors and number of neurological surgeries
- Among indication type, the brain metastasis segment is expected to account for a major revenue share by 2027. Brain metastasis is a type of cancer that can spread to the brain from another location in the body and is also considered as secondary brain tumor.
- Major players operating in the global gamma knife market include Elekta AB, Varian Medical Systems Inc., Huiheng Medical Inc., Cyber Medical Corporation Limited, Masep Infini Global Inc., ET Medical Group, Nordion Inc., Hokai and GE Healthcare.